Biopharmaceutical company GSK plc (LSE:GSK) (NYSE:GSK) on Friday announced progress with two of its cancer drugs.
The European Medicines Agency (EMA) has validated GSK's marketing authorisation application for momelotinib, a potential new oral treatment for an uncommon type of bone marrow cancer known as myelofibrosis.
If approved by regulators, momelotinib would be the only medicine that addresses key manifestations of myelofibrosis.
Regulatory action by the Committee for Medicinal Products for Human Use (CHMP) is anticipated by the end of 2023. A New Drug Application for momelotinib is also currently under regulatory review with the US Food and Drug Administration (FDA), with a Prescription Drug User Fee Act action date of 16 June 2023.
Separately, GSK announced positive headline results from a phase III trial of Jemperli (dostarlimab) in patients with primary advanced or recurrent endometrial cancer. The trial met its primary endpoint and the treatment showed a "statistically significant and clinically meaningful benefit".
Regulatory submissions based on the trial results are anticipated in the first half of 2023.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial